Health & Fitness
Health and Fitness
Health and Fitness
Tue, February 15, 2011Mon, February 14, 2011Fri, February 11, 2011Thu, February 10, 2011Wed, February 9, 2011Tue, February 8, 2011Mon, February 7, 2011Sun, February 6, 2011Fri, February 4, 2011Thu, February 3, 2011Wed, February 2, 2011Tue, February 1, 2011Mon, January 31, 2011Sun, January 30, 2011Fri, January 28, 2011Thu, January 27, 2011XenoPort to Release Fourth Quarter and Year-End Financial Results on February 16, 2011
Published in Health and Fitness on Tuesday, February 8th 2011 at 3:20 GMT by Market Wire
SANTA CLARA, Calif.--([ BUSINESS WIRE ])--XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its fourth quarter financial results on February 16, 2011 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.
To access the conference call via the Internet, go to [ www.XenoPort.com ]. Please join the call at least 15 minutes prior to the start to ensure time for any software downloads that may be required.
To access the live conference call via phone, dial 1-888-275-3514. International callers may access the live call by dialing 706-679-1417. The reference number to enter the call is 43014870.
The replay of the conference call may be accessed that same day after 8:00 p.m. Eastern Time, via the Internet, at [ www.XenoPort.com ], or via phone at 1-800-642-1687 for domestic callers, or 706-645-9291 for international callers. The reference number to enter the replay of the call is 43014870.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the bodya™s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in collaboration with Astellas Pharma Inc. and GlaxoSmithKline. XenoPorta™s product candidates are being studied for the potential treatment of restless legs syndrome, gastroesophageal reflux disease, neuropathic pain, spasticity and Parkinsona™s disease. To learn more about XenoPort, please visit the web site at [ www.XenoPort.com ].
XenoPort is a registered trademark of XenoPort, Inc.
XNPT2F
